公开(公告)号：US20250049927A1

公开(公告)日：2025-02-13

申请号：US18720525

申请日：2022-11-08

Applicant: INTEROLIGO CORPORATION.

Inventor： JUNG HWAN LEE ,  JONG OOK LEE

IPC: A61K47/54 ,  A61K33/243 ,  A61K38/07

Abstract: A modified oligonucleotide including at least one modified nucleic acid, and a modified oligonucleotide-drug conjugate including a drug conjugated to the modified oligonucleotide. The modified oligonucleotide-drug conjugate exhibits high stability in the body and may exhibit an excellent anticancer effect. In a method for treating a cancer, the modified oligonucleotide-drug conjugate is administered to a subject in need thereof.

公开(公告)号：US12214047B2

公开(公告)日：2025-02-04

申请号：US17348043

申请日：2021-06-15

Applicant: Trustees of Tufts College

Inventor： William W. Bachovchin ,  Hung-sen Lai ,  Sarah E. Poplawski

IPC: A61K31/69 ,  A61K38/07 ,  A61K45/06 ,  A61K47/54 ,  A61K47/64 ,  C07K5/062 ,  C07K5/065 ,  C07K5/083 ,  C07K5/087 ,  C07K5/097 ,  C07K5/107 ,  G01N33/574 ,  A61K38/00

Abstract: Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.

公开(公告)号：US12214009B2

公开(公告)日：2025-02-04

申请号：US18212119

申请日：2023-06-20

Applicant: Alastin Skincare, Inc.

Inventor： Alan David Widgerow ,  John A. Garruto

IPC: A61K38/06 ,  A61K9/00 ,  A61K9/127 ,  A61K38/07 ,  A61K38/08 ,  A61K38/40 ,  A61P17/00 ,  A61P31/04

Abstract: Compositions and methods for improving bruising, stimulating elastin and/or collagen production, stimulating intrinsic hyaluronic acid production, stimulating adipogenesis, reducing inflammation, or combinations thereof are provided herein. Compositions and methods described herein may be used following a cosmetic procedure.

公开(公告)号：US20250011792A1

公开(公告)日：2025-01-09

申请号：US18709695

申请日：2022-11-30

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  FONDATION IMAGINE ,  UNIVERSITÉ PARIS CITÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Olivier HERMINE ,  Mirjana WEIMERSHAUS ,  Thiago TROVATI MACIEL ,  Peter VAN ENDERT ,  Michael DUSSIOT ,  Rachel RIGNAULT-BRICARD ,  Caroline CARVALHO

IPC: C12N15/113 ,  A61K31/351 ,  A61K31/381 ,  A61K31/4433 ,  A61K31/4709 ,  A61K38/07 ,  A61K38/12

Abstract: Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors and other inflammatory molecules via the constitutive pathway that remains ill-defined. Here the inventors describe a role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-α and IL-6 in mast cells and macrophages. IRAP-deficient mice are protected from TNF-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF fails to be efficiently exported from the Golgi. Chemical targeting of IRAP+ endosomes reduced pro-inflammatory cytokine secretion thereby highlighting this compartment as a promising target for the therapeutic control of inflammation. Thus the present invention relates to the use of IRAP inhibitors for the treatment of inflammatory diseases

公开(公告)号：US20250009836A1

公开(公告)日：2025-01-09

申请号：US18653869

申请日：2024-05-02

Applicant: CITY OF HOPE

Inventor： Ravi SALGIA ,  Atish MOHANTY

IPC: A61K38/07 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N15/113

Abstract: Disclosed herein are methods and compositions for alleviating resistance to chemotherapy in a subject using one or more therapeutic agents that perturb the interaction between integrin β4 (ITGB4) and paxillin (PXN), e.g., by inhibiting the expression of ITGB4, PXN, or both. Also disclosed is a combinational therapy for treating cancer with a chemotherapeutic agent such as cisplatin or carboplatin and an inhibitor of ITGB4, PXN or both, such as carfilzomib.

公开(公告)号：US12180269B2

公开(公告)日：2024-12-31

申请号：US17837943

申请日：2022-06-10

Applicant: Rutgers, The State University of New Jersey

Inventor： Renata Pasqualini ,  Wadih Arap ,  Fernanda Iamassaki Staquicini ,  Fortunato Ferrara ,  Sara D'Angelo ,  Andrew R. M. Bradbury

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/574 ,  A61K38/07 ,  A61K39/00 ,  A61K49/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/28 ,  C12N15/10 ,  C12N15/64 ,  C12Q1/6869 ,  G01N33/50

Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

公开(公告)号：US20240358824A1

公开(公告)日：2024-10-31

申请号：US18194864

申请日：2023-04-03

Applicant: PULMOTECT, INC. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  BAYLOR COLLEGE OF MEDICINE

Inventor： BURTON DICKEY ,  SCOTT EVANS ,  BRIAN GILBERT ,  DIANE MARKESICH ,  MICHAEL TUVIM ,  BRENTON SCOTT

IPC: A61K39/39 ,  A61K9/00 ,  A61K31/215 ,  A61K31/24 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K39/00 ,  A61K45/06

CPC classification number: A61K39/39 ,  A61K9/0078 ,  A61K31/215 ,  A61K31/24 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  A61K2039/55561 ,  Y02A50/30

Abstract: Embodiments are directed to compositions and methods for treating viral infections.

公开(公告)号：US20240342290A1

公开(公告)日：2024-10-17

申请号：US18674657

申请日：2024-05-24

Applicant: OneSkin, Inc. ,  UNIVERSIDADE CATÓLICA DE BRASÍLIA ,  UNIÃO BRASILEIRA DE EDUCAÇÃO CATÓLICA, BRASÍLIA

Inventor： Alessandra ZONARI ,  Carolina Reis de OLIVEIRA ,  Edgar Andres OCHOA ,  Juliana Lott de CARVALHO ,  Lear BRACE ,  Mariana BORONI ,  Mylieneth GUIANG ,  Octávio FRANCO ,  William Farias PORTO ,  Thuany de Alencar e SILVA

IPC: A61K47/42 ,  A61K9/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/16 ,  A61K47/46 ,  A61K47/55 ,  C07K7/06

CPC classification number: A61K47/42 ,  A61K9/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/16 ,  A61K47/46 ,  A61K47/551 ,  C07K7/06

Abstract: Polypeptides which can provide a senotherapeutic effect are provided herein. The polypeptides can be formulated for topical application and can be applied topically to a subject to provide a senotherapeutic effect in the subject or in the cells of the subject.

公开(公告)号：US12115227B2

公开(公告)日：2024-10-15

申请号：US16069391

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Lene Schantz Harlow ,  Timothy Warren Paul ,  Brendan M. Mayhugh ,  Kelly Ann Roby ,  Gregory Allan Sacha ,  Xiaona Jing ,  Andrew Hagarman ,  Cale Halbleib

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/19 ,  A61K38/07 ,  A61K47/18 ,  A61K47/26 ,  A61K47/68 ,  A61K47/69 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K47/6849 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/07 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6921 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73

Abstract: Disclosed herein are surfactant free antibody and antibody-drug-conjugate (ADC) formulations for anti-AXL antibodies and ADCs, including aqueous formulations, lyophilized formulations, and reconstituted formulations, as well as related processes and uses. The formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative or other similarly hydrophobic drugs. Some formulations comprise histidine and mannitol.

公开(公告)号：US20240316146A1

公开(公告)日：2024-09-26

申请号：US18260677

申请日：2022-01-07

Applicant: Bexion Pharmaceuticals Inc.

Inventor： Ray Takigiku ,  Darren P. Wolfe ,  Anne Mary Noonan ,  Robert Wesolowski ,  Charles A. Cruze, III ,  Gilles Hugues Tapolsky ,  Richard Charles Curry, III ,  Michael Gazda

IPC: A61K38/17 ,  A61K9/127 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/282 ,  A61K31/335 ,  A61K31/337 ,  A61K31/381 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/69 ,  A61K31/7048 ,  A61K33/243 ,  A61K38/07 ,  A61K39/395 ,  A61K45/06 ,  A61K47/24 ,  A61P35/00

CPC classification number: A61K38/1709 ,  A61K9/127 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/282 ,  A61K31/335 ,  A61K31/337 ,  A61K31/381 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/69 ,  A61K31/7048 ,  A61K33/243 ,  A61K38/07 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/24 ,  A61P35/00

Abstract: Disclosed herein are methods for reducing neuropathy and neuropathic symptoms and/or promoting neurogenesis, neuritogenesis, neuroprotection and neuroregeneration using saposin C-phospholipid compositions. Also disclosed are methods for treating cancer by administering a saposin C-phospholipid nanovesicle formulation and one or more antineoplastic agents or immune checkpoint inhibitors, and kits for the treatment of cancer comprising, in separate containers, (a) a saposin C-phospholipid pharmaceutical composition, and (b) a pharmaceutical composition containing an antineoplastic agent or a pharmaceutical composition containing an immune checkpoint inhibitor.